WRITE 9-10 SENTENCES FOR YOUR RESPONSE: how much common stock, how much in retained earnings and the dividend yield for information below Information Amid the fierce war being waged against cancer by drug developers, there's a biotech segment growing at lightning speed (+20% CAGR)... they're front and center in the oncology space. That segment is known as checkpoint blockade immunotherapy (or immune checkpoint inhibitors). You can be forgiven if you're unfamiliar with the sector, but we urge you to read on to learn more about this exciting opportunity. Projected to reach more than $56.5 billion by 2025, the global immune checkpoint inhibitors market is growing at CAGR of 20.1% it's the fastest growing segment of immuno-oncology. Accompanying that market is a currently little-known company whose flagship drug is poised to be combined with two highly anticipated drugs from multi-billion dollar giants, whose combined values are forecasted to be approximately $17 billion by 2024. That company is Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is a development stage biotech company developing an immuno-oncology virus (called pelareorep) that's currently being studied in combination with Opdivo from Bristol-Myers Squibb Company (NYSE:BMY), Roche's Tecentriq, Pfizer's & Merck KGaA's Bavencio, as well as keytruda from Merck & Co., Inc. (NYSE:MRK). POWER-PACKED COMBOS WITH PHARMA GIANTS Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is currently focused on combining its flagship pelareorep's broad applicability to boost the effectiveness of a range of the biggest names in the immunotherapy sector across multiple cancer indications - including studies with Bavencio Keytruda. Opdivo and Tecentriq". With an immediate focus on checkpoint inhibitors, Oncolytics' primary objective is to obtain regulatory approval for pelareorep as quickly as possible. Pelareorep comes with very compelling metastatic breast cancer survival data, and synergies with approved checkpoint inhibitors and positive clinical biomarker data. The company's second objective is to expand pelareorep into commercially valuable new treatment areas including other immunotherapy agents in collaboration with pharmaceutical partners. Oncolytics has established a successful partnership with Adlai Nortye in China Hong Kong, Macau, Singapore, South Korea and Taiwan. As per the relationship, there is an upfront and milestone payments of up to 586.6 million, with $65 million tied to potential development expansion. But perhaps most notable are the 4 ongoing studies Oncolytics is performing with Pfizer, Merck KGaA, Merck, Bristol-Myers Squibb and Roche. These involve checkpoint inhibitors, targeting metastatic breast cancer, early stage breast cancer, multiple myeloma and pancreatic cancer. Pfizer Bavencio Co-Development Share Price: $36.22 Pfizer Pfizer Inc. Merck KGaA (NYSE:PFE) (MRK:GR) Share Price: 119.50 Market Cap: +$200 Billion Market Cap: +C52 Billion Oncolytics entered into a co-development agreement with Pfizer and Merck KGaA to develop pelareorep in combination with paclitaxel and Bavencio", a human anti-PD-L1 antibody, for the treatment of hormone-receptor positive, metastatic breast cancer. Sales of Bavencio more than tripled from US$23 million in 2017, to-US$75.5 million in 2018. Oncolytics and Pfizer will share costs associated with the phase 2 clinical trial, an open label study that will enroll 48 patients into three cohorts: paclitaxel alone (15), paclitaxel in combination with pelareorep and paclitaxel in combination with both pelareorep (15) and avelumab (18) Roche Tecentriq Collaboration Roche Holding AG (OTC-RHHBY) Share Price: $36.46 Roche Market Cap: +5248 Billion Oncolytics entered into a Master Clinical Supply Agreement with Roche to supply atezolizumab (Tecentriq) at no cost for use in the company's clinical development program. The supply agreement enables Oncolytics to further investigate pelareorep's impact on cancer treatments in combination with atezolizumab and has already been incorporated into the company's clinical program with the SOLTI WOO study in breast cancer. Sales of Tecentriq totaled $766 million in 2018 | Data from the current study with Tecentriq will broaden Oncolytics' experience with the entire drug class as the company looks to demonstrate the impact of pelareorep with checkpoint inhibitors. Under this five-year Master Clinical Supply Agreement, Roche will supply Tecentric for the proposed clinical trial with both parties having access to the clinical data. Merck Keytruda Combination Merck & Co. (NYSE:MRK) Share Price: $82.91 MERCK Market Cap: +$212 Billion Oncolytics is combining pelareorep with Merck's anti-PD-1, pembrolizumab (Keytruda), in an Investigator Sponsored Trial (IST). The goal is to expand the use of checkpoint inhibitors as anti- cancer agents by promoting an inflamed phenotype in the tumor or turning cold tumors hot. Sales of Keytruda were $7.2 billion in 2018 (5) The study in second line pancreatic cancer will enroll approximately 40 patients with advanced pancreatic cancer. Bristol-Myers Squibb Opdivo Combination Bristol-Myers Squibb (NYSE:BMY) M Share Price: $50.22 Market Cap: +$82 Billion Bristol-Myers Squibb Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is combining pelareorep and nivolumab (Opdivo) from Bristol-Myers Squibb with a proteasome inhibitor for patients with relapsed/refractory multiple myeloma. The study expands on Oncolytics' strategy of investigating the importance of systemic pelareorep administration followed by checkpoint blockade. Sales of Opdivo were $6.7 billion in 2018 (5) This combination study will not only help demonstrate the specific role of pelareorep in promoting an inflamed phenotype: turning cold tumors hot. WRITE 9-10 SENTENCES FOR YOUR RESPONSE: how much common stock, how much in retained earnings and the dividend yield for information below Information Amid the fierce war being waged against cancer by drug developers, there's a biotech segment growing at lightning speed (+20% CAGR)... they're front and center in the oncology space. That segment is known as checkpoint blockade immunotherapy (or immune checkpoint inhibitors). You can be forgiven if you're unfamiliar with the sector, but we urge you to read on to learn more about this exciting opportunity. Projected to reach more than $56.5 billion by 2025, the global immune checkpoint inhibitors market is growing at CAGR of 20.1% it's the fastest growing segment of immuno-oncology. Accompanying that market is a currently little-known company whose flagship drug is poised to be combined with two highly anticipated drugs from multi-billion dollar giants, whose combined values are forecasted to be approximately $17 billion by 2024. That company is Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is a development stage biotech company developing an immuno-oncology virus (called pelareorep) that's currently being studied in combination with Opdivo from Bristol-Myers Squibb Company (NYSE:BMY), Roche's Tecentriq, Pfizer's & Merck KGaA's Bavencio, as well as keytruda from Merck & Co., Inc. (NYSE:MRK). POWER-PACKED COMBOS WITH PHARMA GIANTS Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is currently focused on combining its flagship pelareorep's broad applicability to boost the effectiveness of a range of the biggest names in the immunotherapy sector across multiple cancer indications - including studies with Bavencio Keytruda. Opdivo and Tecentriq". With an immediate focus on checkpoint inhibitors, Oncolytics' primary objective is to obtain regulatory approval for pelareorep as quickly as possible. Pelareorep comes with very compelling metastatic breast cancer survival data, and synergies with approved checkpoint inhibitors and positive clinical biomarker data. The company's second objective is to expand pelareorep into commercially valuable new treatment areas including other immunotherapy agents in collaboration with pharmaceutical partners. Oncolytics has established a successful partnership with Adlai Nortye in China Hong Kong, Macau, Singapore, South Korea and Taiwan. As per the relationship, there is an upfront and milestone payments of up to 586.6 million, with $65 million tied to potential development expansion. But perhaps most notable are the 4 ongoing studies Oncolytics is performing with Pfizer, Merck KGaA, Merck, Bristol-Myers Squibb and Roche. These involve checkpoint inhibitors, targeting metastatic breast cancer, early stage breast cancer, multiple myeloma and pancreatic cancer. Pfizer Bavencio Co-Development Share Price: $36.22 Pfizer Pfizer Inc. Merck KGaA (NYSE:PFE) (MRK:GR) Share Price: 119.50 Market Cap: +$200 Billion Market Cap: +C52 Billion Oncolytics entered into a co-development agreement with Pfizer and Merck KGaA to develop pelareorep in combination with paclitaxel and Bavencio", a human anti-PD-L1 antibody, for the treatment of hormone-receptor positive, metastatic breast cancer. Sales of Bavencio more than tripled from US$23 million in 2017, to-US$75.5 million in 2018. Oncolytics and Pfizer will share costs associated with the phase 2 clinical trial, an open label study that will enroll 48 patients into three cohorts: paclitaxel alone (15), paclitaxel in combination with pelareorep and paclitaxel in combination with both pelareorep (15) and avelumab (18) Roche Tecentriq Collaboration Roche Holding AG (OTC-RHHBY) Share Price: $36.46 Roche Market Cap: +5248 Billion Oncolytics entered into a Master Clinical Supply Agreement with Roche to supply atezolizumab (Tecentriq) at no cost for use in the company's clinical development program. The supply agreement enables Oncolytics to further investigate pelareorep's impact on cancer treatments in combination with atezolizumab and has already been incorporated into the company's clinical program with the SOLTI WOO study in breast cancer. Sales of Tecentriq totaled $766 million in 2018 | Data from the current study with Tecentriq will broaden Oncolytics' experience with the entire drug class as the company looks to demonstrate the impact of pelareorep with checkpoint inhibitors. Under this five-year Master Clinical Supply Agreement, Roche will supply Tecentric for the proposed clinical trial with both parties having access to the clinical data. Merck Keytruda Combination Merck & Co. (NYSE:MRK) Share Price: $82.91 MERCK Market Cap: +$212 Billion Oncolytics is combining pelareorep with Merck's anti-PD-1, pembrolizumab (Keytruda), in an Investigator Sponsored Trial (IST). The goal is to expand the use of checkpoint inhibitors as anti- cancer agents by promoting an inflamed phenotype in the tumor or turning cold tumors hot. Sales of Keytruda were $7.2 billion in 2018 (5) The study in second line pancreatic cancer will enroll approximately 40 patients with advanced pancreatic cancer. Bristol-Myers Squibb Opdivo Combination Bristol-Myers Squibb (NYSE:BMY) M Share Price: $50.22 Market Cap: +$82 Billion Bristol-Myers Squibb Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is combining pelareorep and nivolumab (Opdivo) from Bristol-Myers Squibb with a proteasome inhibitor for patients with relapsed/refractory multiple myeloma. The study expands on Oncolytics' strategy of investigating the importance of systemic pelareorep administration followed by checkpoint blockade. Sales of Opdivo were $6.7 billion in 2018 (5) This combination study will not only help demonstrate the specific role of pelareorep in promoting an inflamed phenotype: turning cold tumors hot